- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00415077
A Comparison of Photorefractive Keratectomy (PRK), PRK With Mitomycin-C and Laser Subepithelial Keratomileusis (LASEK) in the Treatment of Moderate and High Myopia
July 15, 2010 updated by: Walter Reed Army Medical Center
A Prospective Comparison of Photorefractive Keratectomy (PRK), PRK With Mitomycin-C and Laser Subepithelial Keratomileusis (LASEK) in the Treatment of Moderate and High Myopia
The purpose of this study is to assess whether there is a significant difference in visual outcomes or corneal haze after surface ablation for moderate and high myopia in active duty service members treated with PRK, Mitomycin-C (MMC) PRK and LASEK.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
960
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20307
- Walter Reed Army Medical Center, Center For Refractive Surgery
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Informed consent.
- Normal, healthy, active duty adults age 21 years or older. The lower age limit of 21 years is intended to ensure documentation of refractive stability.
- Manifest refractive spherical equivalent of greater than -4.00 diopters (D) up to -10.00 D.
- Best spectacle corrected visual acuity of 20/20 or better in both eyes.
- Demonstrated refractive stability, confirmed by clinical records. Neither the spherical nor the cylindrical portion of the refraction may have changed more than 0.50D during the 12-month period immediately preceding the baseline examination, as confirmed by clinical records.
- Both eyes must fall in the same refraction group and there must be less than 1 D difference between eyes.
- Soft contact lens users must have removed their lenses at least 2 weeks before baseline measurements. Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least 4 weeks prior to baseline measurements and have 2 central keratometry readings and 2 manifest refractions taken at least 1 week apart that do not differ by more than 0.50 D in either meridian.
- Access to transportation to meet the follow-up requirements.
- Available for evaluation during the 1-year follow-up period.
- Consent of the subject's command to participate in the study.
Exclusion Criteria:
- Female subjects who are pregnant, breast-feeding or intend to become pregnant during the study. Women of childbearing age will take a urine pregnancy test before starting this study.
- Residual, recurrent or active ocular diseases or corneal abnormalities in either eye such as keratoconus, iritis, uveitis, keratoconjunctivitis sicca, vernal conjunctivitis, lagophthalmos, corneal scarring, glaucoma, previous steroid responder, occludable chamber angles, visually significant cataracts.
- Medical condition(s), which, in the judgment of the investigator, may impair healing, including but not limited to: collagen vascular disease, autoimmune disease, immunodeficiency diseases, and ocular herpes zoster or simplex.
- Concurrent topical or systemic medications that may impair healing, including corticosteroids, antimetabolites, isotretinoin (Accutane), amiodarone hydrochloride (Cordarone) and/or sumatripin (Imitrex).
- Any physical or mental impairment that would preclude participation in any of the examinations.
- Prior refractive or ocular surgery.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 2
LASEK- laser-assisted subepithelial keratectomy
|
mitomycin C PRK
|
Active Comparator: 3
Mitomycin C PRK
|
LASEK
|
Active Comparator: 1
PRK- Photorefractive keratectomy
|
PRK
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy in terms of uncorrected visual acuity and post operative refraction. Safety in terms of maintenance of best spectacle corrected acuity within 2 lines of preoperative levels.
Time Frame: 12 months after surgery
|
12 months after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: KRAIG S BOWER, MD, DIRECTOR, CENTER FOR REFRACTIVE SURGERY WALTER REED ARMY MEDICAL CENTER
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2004
Study Registration Dates
First Submitted
December 21, 2006
First Submitted That Met QC Criteria
December 21, 2006
First Posted (Estimate)
December 22, 2006
Study Record Updates
Last Update Posted (Estimate)
July 16, 2010
Last Update Submitted That Met QC Criteria
July 15, 2010
Last Verified
July 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WRAMC WU# 04-23009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MODERATE AND HIGH MYOPIA
-
Beijing Airdoc Technology Co., Ltd.University of Notre Dame AustraliaRecruitingAstigmatism | Myopia | Myopia, ModerateChina
-
Shanghai Eye Disease Prevention and Treatment CenterShanghai General Hospital, Shanghai Jiao Tong University School of MedicineEnrolling by invitationHigh Myopia | Pathologic MyopiaChina
-
Shanghai Eye Disease Prevention and Treatment CenterNot yet recruiting
-
The Hong Kong Polytechnic UniversityAston University; Queensland University of TechnologyRecruiting
-
Sun Yat-sen UniversitySuspended
-
The First Affiliated Hospital of Zhengzhou UniversityCompleted
-
Poitiers University HospitalCompleted
-
Shanghai Eye Disease Prevention and Treatment CenterShanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Shandong University of Traditional Chinese MedicineNot yet recruiting
-
Tianjin Eye HospitalActive, not recruitingMyopia | High MyopiaChina
Clinical Trials on MMC PRK
-
Assiut UniversityCompleted
-
University of UtahCompleted
-
Fort Belvoir Community HospitalWalter Reed National Military Medical Center; US Army Night Vision and Electronic...CompletedMyopia | Myopic AstigmatismUnited States
-
Walter Reed Army Medical CenterCompleted
-
Assiut UniversityCompletedMyopia ≤ -6 Diopters or Myopic Astigmatism ≤ -4 DioptersEgypt
-
University of UtahCompleted
-
University of AarhusCompleted
-
UroGen Pharma Ltd.CompletedCarcinoma of Urinary Bladder, SuperficialIsrael, Spain, Italy, Switzerland
-
Moorfields Eye Hospital NHS Foundation TrustCompletedRefractive Errors | Lens Diseases | Satisfaction | CorneaUnited Kingdom